Life after treatment for follicular lymphoma brings long-term physical and emotional challenges, including immune system ...
The author of the ‘Leonard List’ that highlights emerging hematologic research to be presented at annual ASH meetings is also ...
Pharmaceutical Technology on MSN7d
China conditionally approves Hutchmed’s Tazverik for follicular lymphomaChina’s National Medical Products Administration (NMPA) has granted conditional approval for Hutchmed’s Tazverik ...
Wojciech Jurczak, MD, PhD, ​​discusses nemtabrutinib and its development for the treatment of follicular lymphoma.
Pharmaceutical Technology on MSN11d
EC approves Bristol Myers Squibb’s follicular lymphoma CAR T therapyThe European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...
Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...
It usually responds well to treatment and is often cured. About one in five people with lymphoma have follicular lymphoma. This is a slow-growing form that mainly affects older adults. It might ...
TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.
FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from TELLOMAK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback